Skip to main content
. Author manuscript; available in PMC: 2015 May 18.
Published in final edited form as: J Biomol Screen. 2012 Dec 10;18(6):647–658. doi: 10.1177/1087057112469405

Figure 2.

Figure 2

Dose-dependence confirmation of select fibulin-3–reducing compounds. ARPE19 cells expressing eGLuc2, wild-type (WT) fibulin-3–eGLuc2 (WT-eGLuc2), or R345W fibulin-3–eGLuc2 (R345W-eGLuc2) were treated with the indicated compounds for 24 h, after which the secreted (A, C, E) or intracellular accumulation of each eGLuc2 variant was measured (B, D, F). n = 3, ± SD.